CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

Science

Volumn 331, Issue 6024, 2011, Pages 1612-1616

  Beatty, Gregory L ^a,d   Chiorean, Elena G ^b   Fishman, Matthew P ^a   Saboury, Babak ^d   Teitelbaum, Ursina R ^a,d   Sun, Weijing ^a,d   Huhn, Richard D ^c   Song, Wenru ^c   Li, Dongguang ^c   Sharp, Leslie L ^c   Torigian, Drew A ^a,d   O'Dwyer, Peter J ^a,d   Vonderheide, Robert H ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CP 870893; GEMCITABINE;

CANCER; CHEMOTHERAPY; HOMINID; IMMUNE RESPONSE; IMMUNITY; RODENT; TUMOR;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOKINE RELEASE; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; GENETIC ENGINEERING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MACROPHAGE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS DUCT ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RIGOR; STROMA; TUMOR IMMUNITY;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC SURVEILLANCE; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MIDDLE AGED; PANCREATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; YOUNG ADULT;

MUS;

EID: 79953154967     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1198443     Document Type: Article

References (24)

1. H. A. Burris 3rd et al., J. Clin. Oncol. 15, 2403 (1997).
2. C. E. Clark et al., Cancer Res. 67, 9518 (2007).
3. S. P. Schoenberger, R. E. Toes, E. I. van der Voort, R. Offringa, C. J. Melief, Nature 393, 480 (1998).
4. S. R. Bennett et al., Nature 393, 478 (1998).
5. J. P. Ridge, F. Di Rosa, P. Matzinger, Nature 393, 474 (1998).
6. R. R. French, H. T. Chan, A. L. Tutt, M. J. Glennie, Nat. Med. 5, 548 (1999).
7. L. Diehl et al., Nat. Med. 5, 774 (1999).
8. E. M. Sotomayor et al., Nat. Med. 5, 780 (1999).
9. R. H. Vonderheide et al., J. Clin. Oncol. 25, 876 (2007).
10. Materials and methods are available as supporting material on Science Online.
11. A. K. Nowak, B. W. Robinson, R. A. Lake, Cancer Res. 63, 4490 (2003).
12. R. A. Lake, B. W. Robinson, Nat. Rev. Cancer 5, 397 (2005).
13. D. I. Gabrilovich, Lancet Oncol. 8, 2 (2007).
14. L. Zitvogel et al., J. Clin. Invest. 118, 1991 (2008).
15. S. R. Hingorani et al., Cancer Cell 7, 469 (2005).
16. K. P. Olive et al., Science 324, 1457 (2009).
17. T. Van Dyke, Nat. Med. 16, 976 (2010).
18. R. H. Vonderheide, Clin. Cancer Res. 13, 1083 (2007).
19. C. van Kooten, J. Banchereau, J. Leukoc. Biol. 67, 2 (2000).
20. N. Van Rooijen, A. Sanders, J. Immunol. Methods 174, 83 (1994).
21. L. M. Coussens, Z. Werb, Nature 420, 860 (2002).
22. A. Mantovani, A. Sica, Curr. Opin. Immunol. 22, 231 (2010).
23. E. M. Jaffee et al., J. Clin. Oncol. 19, 145 (2001).
24. We thank C. Abrams, E. Furth, C. June, B. Keith, G. Koretzky, C. Simon, and B. Stanger for helpful discussions. This research was supported by the Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine (R.H.V.) and by NIH grants P30 CA016520 (P.J.O. and R.H.V.) and K12 CA076931 (G.L.B.). The clinical study and part of the preclinical studies were supported by funding from Pfizer Corp (to R.H.V. and P.J.D). W. Song, D. Li, and L. L. Sharp are employees of Pfizer Corp. P. J. O'Dwyer discloses receiving honoraria from Pfizer; D. A. Torigian owns stock in Pfizer. CP-870,893 is owned and patented by Pfizer Corp., which manages its distribution. Although now at a new address, R. D. Huhn was affiliated with Pfizer Corp. during the conduct and analysis of this study. Some of the clinical data were presented at the 2010 American Society of Clinical Oncology Annual Meeting.